The university is not disclosing the amount of the donation. Photo via Rice University

Following a “generous philanthropic gift” by Farid and Asha Virani, the undergraduate business program at Rice University will be named after the family. The building where the business program is housed, McNair Hall, will remain unchanged.

“We are profoundly grateful to Farid and Asha Virani for their extraordinary gift, which will transform our undergraduate business education,” Rice president Reginald DesRoches said in a statement. “Their success and commitment to excellence inspire our students, and their generosity will serve as a lasting testament to what can be accomplished through vision and determination.”

Rice University declined to disclose the size of donation that has led to the creation of the Virani Undergraduate School of Business on the request of the Virani family to maintain privacy, saying only that the amount is historic. The business school currently serves roughly 300 undergrads.

Dr. Asha Virani is a proud Rice alumna who graduated in 1989. Her husband, Farid, is the founder and CEO of Prime Communications, a wildly successful AT&T retailer that started with a single store in Baybrook Mall and has grown to be the largest such retailer in the nation. Their son, Faraz, graduated from Rice in 2021 after studying sports management.

“We are incredibly excited to support Rice Business, as we believe in the transformative power of education. This contribution will play a pivotal role in preparing the next generation of business leaders and entrepreneurs to tackle the challenges and seize the future opportunities — not just for our city, but for our state and our country,” Farid Virani said.

“Our vision is to foster a culture of curious and compassionate lifelong learners who will lead with a strong ethical orientation and intellectual humility,” Asha Virani said.

A new associate dean position will be created to oversee the new business school, and a national talent search is underway to fill the job. The gift will help expand the current business undergraduate offerings, including new major focuses in areas like healthcare and artificial intelligence.

Rice launched its undergraduate business program in 2021. Last year, the university announced its plans to expand its business school, a project that is currently underway.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”